Latest news in cancer
Ibrutinib is approved for pediatric patients with chronic graft versus host disease, including a new oral suspension
Sept 2022: Ibrutinib (Imbruvica, Pharmacyclics LLC) was approved by the Food and Drug Administration for use in paediatric patients with chronic graft versus...
Tecartus granted European marketing authorization for treatment of relapsed or refractory acute lymphoblastic leukemia
Sept 2022: The European Commission (EC) has authorized Kite’s CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) for the treatment of adult...
CAR T-Cell therapy complications can be predicted by a simple blood test
Sept 2022: The treatment of various tumours has been transformed by cell-based immunotherapy, often known as CAR-T cell therapy. In order to target and combat...
New test to determine whether CAR T-Cell therapy will work for lymphoma patients
Sept 2022: According to a study published in the Journal of Clinical Investigation, an engineer at the University of Houston (UH) may have discovered a...
Claudin 18.2 and its role in advanced gastric cancers
August 2022: The most apical portion of polarised epithelial and endothelial cells contains tight junctions, which are specialised membrane domains. The...
Accelerated approval is granted by FDA to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer
August 2022: For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation resulting in mesenchymal-epithelial...
Capmatinib is approved for metastatic non-small cell lung cancer
August 2022: For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation resulting in mesenchymal-epithelial...
Darolutamide tablets is approved by FDA for metastatic hormone-sensitive prostate cancer
August 2022: Darolutamide (Nubeqa, Bayer HealthCare Pharmaceuticals Inc.) tablets combined with docetaxel were approved by the Food and Drug Administration...
Fam-trastuzumab deruxtecan-nxki is approved by FDA for HER2-low breast cancer
August 2022: For adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH) breast cancer who have received prior chemotherapy in the...
Crizotinib is approved by FDA for ALK-positive inflammatory myofibroblastic tumor
July 2022: Crizotinib (Xalkori, Pfizer Inc.) was granted approval by the Food and Drug Administration (FDA) for the treatment of adult and paediatric...
A memorandum of understanding (MOU) has been signed by GenScript ProBio to form a strategic partnership with ACT Therapeutics to develop new CAR-T cell therapies
July 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a...
CAR T-Cell therapy market will grow at phenomenal rate in next 8 years
July 2022: According to the most recent research conducted by Emergen Research, the global market for CAR T-cells therapy reached a size of USD 1.29...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.